Michael Hewitt, PhD

Mike is Vice President, CMC at Sionna and has 20 years of development experience in the pharmaceutical industry. Prior to Sionna, Mike was CMC lead for ALKS-1140 at Alkermes after their acquisition of Rodin Therapeutics. At Rodin, Mike was responsible for all aspects of CMC for Rodin’s clinical CoREST-selective HDAC inhibitors.

Mike spent 6 years at Constellation Pharmaceuticals where he was a medicinal chemist on the Pelabresib/CPI-0610 team (currently in Phase 3), project manager for the CPI-1205 IND and a CMC leader for CPI-0610 and CPI-1205. He began his career at Sepracor/Sunovion as a medicinal chemist and was an inventor of Ulotaront/SEP-363856, currently in Phase 3 clinical trials for Schizophrenia.

Mike received his Ph.D. in organic chemistry from MIT and his A.B. in chemistry from the College of the Holy Cross.